Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study
Most tuberculosis-related deaths in people with HIV could be prevented with earlier diagnosis and treatment
Abstract
Most tuberculosis-related deaths in people with HIV could be prevented with earlier diagnosis and treatment. The only commercially available tuberculosis point-of-care test (Alere Determine TB LAM Ag [AlereLAM]) has suboptimal sensitivity, which restricts its use in clinical practice. The novel Fujifilm SILVAMP TB LAM (FujiLAM) assay has been developed to improve the sensitivity of AlereLAM.
The authors assessed the diagnostic accuracy of the FujiLAM assay for the detection of tuberculosis in hospital inpatients with HIV compared with the AlereLAM assay.
This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)
Citation
Harries AD, Takarinda KC. F1000Prime Recommendation of [Broger T et al., Lancet Infect Dis 2019 19(8):852-861]. F1000 Prime. 2019. Available from: https://f1000.com/prime/735861412#eval793564109